プログラム

Final Agenda

5月7日(月)

8:00 am Workshop Registration and Morning Coffee

9:00 am - 12:00 pm Pre-Conference Workshop*: The Key Skills of the Alliance Manager: Models, Tools and Frameworks for Maximum Impact

All Alliance Managers want to have impact, and most have the natural core skills to do so. That said, to have true impact, Alliance Managers need to move beyond their natural ideas and inclinations, and get ever more systematic and clear about their approach, and get better at applying specific models and tools to their role. In this highly interactive, experiential and case study-based workshop, Alliance Managers will learn about, discuss and practice using an Alliance Manager toolkit that, coming out of the session, will enable them to both immediately and continually over time enhance their ability to make a real and positive impact on their alliances and those alliances' ability to execute toward their goals.

Instructor: Renee Jansen, JD, Principal, Vantage Partners


*Separate registration required

12:00 pm Main Conference Registration

1:10 Chairperson's Opening Remarks and Welcome

Kip Harry, Senior Director, Conferences, Cambridge Healthtech Institute

アイスブレーキング

1:15 Big Pharma-Biotech Back-and-Forth: Tell Me What's Wrong, and How I Can Help!

Dana Hughes, Vice President & Global Head, Integration and Alliance Management, Worldwide Business Development Group, Pfizer

Join a frank and open discussion involving all conference participants on the real issues surrounding managing partnerships between large and small companies. Often, each side is unaware of how to improve to better align with their partner. This session provides attendees with insights into critical pain-points from the perspective of each side, while offering best practices to alleviate common issues, and real-time problem-solving for more difficult issues.

有効な戦略的提携管理を導入し提携能力を構築するための第1歩

2:15 Shaping a New Company Capability in Alliance Leadership

Mark Coflin, Head, Alliance Management, Corporate Planning & Program Management, Shire

Shaping a new company with an innovative approach to Alliance Management leadership is an exciting opportunity! Shire is the leading rare disease-focused biotech focused on rare disease targeting highly specialized conditions. This presentation will discuss key learnings on designing and building the organizational Alliance Management capability, championing change and overcoming obstacles in the journey. This presentation will share the vision of success, the roadmap, and practical tips for everyone.

3:00 People in Alliance Management

Lena Frank, Executive Director, Program & Alliance Management, Oncology Business Group, Eisai Inc.

Whether you are considering hiring your first alliance manager, developing an alliance management group or looking to transform your group, there are a number of factors to consider: 1. Should alliance management be a standalone function? 2. Is there a difference between alliance management and project management? 3. What skill sets and capabilities are needed in alliance management? 4. How do you find your next alliance manager?

3:30 Networking Refreshment Break with Exhibit Viewing

提携による可能性を高め、文化を醸成させるための戦略

4:10 Chairperson's Remarks

Mark Coflin, Head, Alliance Management, Corporate Planning & Program Management, Shire

4:15 Alliance Capability - How to Develop a Corporate Capability and Explore the Upsides for the Organization

Michael Kennedy, PhD, MBA, Director, Alliance Management, Business Development & Licensing, Bayer HealthCare

Developing a true alliance capability takes time and goes through many stages, from establishing the role of alliance management through delivering a function-level capability to realizing a true corporate capability. A collaboration-savvy organization has upsides - empowered teams, increased capability to problem-solve, ability to innovate and manage organizational change.

4:45 Building an Alliance Management Culture and Capabilities within Your Company - It Goes a Long Way to Foster Healthy Collaborations and to Be a Preferred Partner

Angela Bylancik, Executive Director BD&L, Alliance Management, Novartis Pharmaceuticals Corporation

This presentation will discuss Novartis's internal program to establish a broader alliance management culture addressing critical aspects of creating true corporate alliance capability, generating value, and selling that value to obtain C-suite support.

 

5:15 Evolving Alliance Management for the Partnering Everywhere World

Jan Twombly, CSAP, President, The Rhythm of Business

The structure, size, scope, and responsibilities of alliance management departments are evolving to address the increasing amount of partnering activity everywhere throughout the business. Based on a recently completed research study covering companies of varying sizes and maturity of alliance management practices, data will be presented to highlight:

  • How the alliance management function is evolving to meet the needs of their internal stakeholders as well as partners
  • The challenges encountered and how they are being addressed

5:45 Welcome Reception with Exhibit Viewing (sponsorship opportunity available)  

7:00 Close of Day

5月8日(火)

7:30 am Registration Open

8:00 Interactive Breakout Discussion Groups and Speed Networking with Continental Breakfast

Grab a cup of coffee and delve deeper into some of the overarching concerns facing alliances today. These are moderated roundtables with brainstorming and interactive problem solving, allowing conference participants from diverse backgrounds to have frank discussion while exchanging ideas, experiences, and developing future collaborations around a focused topic.

Table 1: Alliance Management at the Forefront of Deal-Making

Table 2: Alliance Launch

Table 3: Alliance Management & Project Management - Managing the Divide

Table 4: Introducing Alliance Management to a Growing Biotech Company

Table 5: A Review of Best Practices for Collaborations between Pharmaceutical Companies and Companion Diagnostic Providers

See Healthtech.com/Alliance-US for Details.

新たなフロンティア:技術ベースのパートナーシップ

9:25 Chairperson's Remarks

Kip Harry, Senior Director, Conferences, Cambridge Healthtech Institute

9:30 Case Study: Can Gaming Play Nicely with Pharma

Joseph Koziak, CEO, Executive, Amblyotech Inc.

Amblyotech is a life sciences company that has partnered with Ubisoft, a gaming company. The collaboration created the Amblyotab, a novel, patented medical device to treat Amblyopia, a condition that has remained effectively untreated for over 300 years.

 

10:00 KEYNOTE PRESENTATION: Cracking the Code on Technology-Based Partnerships

Stuart Kliman, JD, Partner, Vantage Partners

Pharma/biotech firms are increasingly pursuing partnerships with technology firms, and other non-traditional partners, to create differentiated value propositions, broaden their customer base, and enable new financial models. Success in these relationships can be difficult given the significant differences between pharma and tech business models. This presentation will focus on how your organization can clarify its purpose for pursuing alliances with technology companies, ensure that these alliances are supportive of your overall business strategy, think holistically about how these new types of alliances fit within your existing ecosystem of relationships, and identify, evaluate, and select potential partners to meet your specific needs.

10:45 Networking Coffee Break with Exhibit Viewing

選ばれるパートナー:BMS, BAYER, SANOFI, GSK, PFIZER, ASTRAZENECA, CELGENE, BOEHRINGERの新たなイニシアチブ検証

11:30 Deploying AM Resources across a Dynamic Alliance Portfolio

Nancy Forrest, Vice President, Global Alliances and Operation, Bristol-Myers Squibb

As companies become more reliant on partnering, alliance portfolio management increases in importance. The portfolio can vary from early stage to late stage assets, 'easy' to 'complex,' and specialty to primary care. Each carries its own unique challenges, but also alliance portfolio challenges as well. In addition, new alliance models, such as clinical collaborations, are emerging, furthering complexity. This session discusses concepts of alliance portfolio management.

12:00 pm Alliance Capability - How to Develop a Corporate Capability and Explore the Upsides for the Organization

Karen Denton, Director, Alliance Management, Bayer Health Care Pharmaceuticals

This presentation will detail a recent initiative at Bayer to develop and implement an over-arching alliance management competency model and associated developmental pathways for both alliance managers and those working on alliances.

12:30 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

2:00 The Sanofi Case Study of Building an Effective Alliance Management Organization

Julia Gershkovich, Head, North America R&D Alliance Management, Sanofi

This presentation will highlight Sanofi's internal efforts for continued organizational improvements, experiences with KPIs on the alliance portfolio, and experiences with internal training of Alliance Management.

2:30 Insights into Alliance Management at GSK

Steven L. Pessagno, Alliance Director and Head of CoE Operations, Alliance Management, Worldwide Business Development, GlaxoSmithKline

Across the life sciences industry, we spend billions each year on collaborations of all sizes and shapes with the hope that by working together, we will deliver more innovative medicines, devices, and diagnostics for patients, and in turn, generate greater value for our shareholders. We all have our own stories to tell on these collaborations and our approaches to working with alliance partners. The GSK approach may be unique. We focus on the evolution of alliance management to address the needs of the diverse types of collaborations we enter into.

3:30 Alliance Management at AbbVie

Anna Maroney, PhD, Vice President & Head, Alliance Management, AbbVie

4:00 Networking Refreshment Break with Exhibit Viewing

4:30 Alliance Management at AstraZeneca

Steve Twait, Vice President, Alliance and Integration Management (AIM), AstraZeneca Pharmaceuticals

5:00 Celgene's Alliance Management - Building Capabilities with Diverse Relationships

Soo Bang, Executive Director, Business Development & Global Alliances, Celgene Corporation

This presentation will provide an overview of Celgene's story, including details on its driving culture, core focus and pipeline, including the alliance management history. Discussion will focus on how we build and manage diverse partnerships and our approach to managing the portfolio of alliances, as well as share what's next for Celgene's partnerships.

5:30 Working Together for Better Health

Mark Ralph, Global Head, Contracts and Alliance Management, Boehringer Ingelheim

Boehringer Ingelheim seeks to establish mutually beneficial collaborations with academic, biotechnology and pharmaceutical partners in areas of strategic interest. We see these partnerships as being critical to the success of our drug discovery efforts and our pursuit of better therapeutics for the patients we serve. This presentation will give an overview of Boehringer Ingelheim, our partnering philosophy and strategic interests, in addition to detailing our approach to alliance management and how we seek to drive collaborations to have mutually beneficial outcomes.

6:00 Close of Day

5月9日(水)

8:00 am Morning Coffee

現状のパートナーシップと提携管理のケーススタディ

8:25 Chairperson's Opening Remarks

Harry Atkins, Senior Director, Corporate Development and Alliance Management, Aralez Pharmaceuticals US, Inc.


8:30 KEYNOTE CO-PRESENTATION AND CASE STUDY: Importance of Alliance Joint-Team Membership Longevity

Dana M. Hammill, Director, Business Development and Alliances, Center for Cellular Immunotherapies, University of Pennsylvania

Simon Bateman, PhD, Executive Director, Global Strategic Alliance Management, Novartis Oncology

During the pre-launch and launch phases of an alliance, the key team players come together and learn how to best work together for mutual achievement of goals. Charters and joint team meetings are established, as well as best practices for meeting execution and communication. As months and years go by, programs, projects, and individuals come and go. This presentation will discuss examples of alliance turnover, how turnover can positively or negatively impact an alliance, and measures that can be taken to ensure that turnover has little impact on the alliance relationships, goals, and achievements.

9:15 Co-Presentation and Case Study: The New AstraZeneca-Aralez Alliance

Harry Atkins, Senior Director, Business Development and Alliance Management, Aralez Pharmaceuticals Inc.

Bill Dwyer, Senior Director, US Alliance Management, AstraZeneca

This co-presentation will provide a case study on a recent alliance between AstraZeneca and Aralez for the rights to branded and authorized generic Toprol-XL in the US. Alliance management and transition activities currently ongoing between AstraZeneca and Aralez Pharmaceuticals will be presented by both alliance managers.

10:00 Networking Coffee Break with Exhibit Viewing

産業界、学術界、患者支援団体のパートナーシップ管理

10:30 Optimizing Academic-Industry Partnerships and the Role of Alliance Management

Joy Dicker, Director, Alliance Management, Mount Sinai Innovation Partners, Mount Sinai Health System

Pharmaceutical and Biotechnology companies are increasingly looking toward Academia for research programs that can turn into new life-saving therapeutics. However, Academic Research organizations are different from Commercial organizations which presents a unique challenge for Alliance Managers.

11:00 Alternative Ways of Working with Academics

Christine Jost, PhD, Director, Alliance Management, R&D Strategy and External Innovation, Sanofi

Sanofi has embarked on a new collaborative program, the Sanofi iAwards. This collaboration involves seven academic partners. The goal is to increase connectivity with academics and bring more innovation to pharma. Attendees will learn more about the Sanofi iAwards and the lessons learned from managing a large multi-party academic alliance.

11:30 Improving Development and Manufacturing Alliances

Jose Ochoa, Chief Business Officer & Head, Animal Health Americas, IDT Biologika Corporation

IDT Biologika offers customers access to highly integrated development and manufacturing services, including one of the most comprehensive quality control and testing programs in the industry. This presentation will highlight the execution and lessons learned from recent alliances IDT Biologika has entered into to provide an end-to-end solution for the manufacture of antibody drug conjugates and live virus filling and finishing services.

12:00 pm Industry Alliances with Advocacy: Strategic Partnerships & Where to Start

Beth Aselage, Patient Advocacy & Discovery & Translational R&D, Retrophin

Quick to be claimed by most biotech organizations, but slow in its actual implementation, the need for industry alliances with advocacy continues to be an overlooked capability within most organizations. Highlighting some of the recent accomplishments in advocacy, and a case study of an existing industry-advocacy pre-clinical research collaboration, the importance of alliance managers in advocacy will become transparent to biotech organizations still working on the implementation of 'patient-centricity.'

12:30 Close of Conference

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。